...Last meeting of the day, so thank you for everyone for sticking with us, and thanks for Jereme to being here as well. Good afternoon, everyone. For those of you that haven't met me yet, my name is Margaret Kaczor and I am the research analyst here at William Blair & Company who covers DexCom. Before we begin, I do have to disclose the fact that I own -- personally own shares of DexCom. And beyond that, you can obtain a complete list of research disclosures or potential conflicts of interest at williamblair.com. As I said, we're very pleased to have CFO, Jereme Sylvain, here with us. DexCom has been a name that probably has been at this conference well over a decade and a core holding, obviously, for a lot of people at the firm and beyond that. But the stocks actually pulled back quite a lot with the recent market downturn. So even as we look out over the next 12-, 18-, 24-plus months, the ROI for us in DexCom is still well in front of us. And our thesis, while it still remains within type...
